Podcasts about Novo Nordisk

Three more suspects, including two affluent New Jersey teens, are now charged in a foiled ISIS-inspired Halloween terror plot, bringing the total to five. The FAA is cutting up to 10% of flights at 40 major airports as the government shutdown enters week six, triggering nationwide delays. President Trump announces a deal with Eli Lilly and Novo Nordisk to slash the cost of popular GLP-1 weight-loss drugs like Wegovy and Ozempic to about $350 through a new program called TrumpRX. Former House Speaker Nancy Pelosi, 85, announces she will not seek reelection after nearly four decades in Congress and two impeachments of President Trump. Geviti: Go to https://gogeviti.com/megynand get 20% off with code MEGYN. Walmart: Learn how Walmart is fueling the future of U.S. manufacturing at https://Walmart.com/America-at-work Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today's Headlines: House Democrats want no-longer-Prince Andrew to testify about his ties to Jeffrey Epstein. Meanwhile, Nancy Pelosi announced her retirement, with California Sen. Scott Wiener emerging as the establishment pick — though AOC's ex–campaign manager Saikat Chakrabarti plans to run too. A federal judge ruled again that Trump must fully fund SNAP benefits by today, but the DOJ is appealing. Trump also struck a deal with Eli Lilly and Novo Nordisk to cap Ozempic-style drugs at $50 for Medicare and Medicaid patients next year. In smaller but iconic justice news, the D.C. “sandwich guy” who threw a sub at an ICE agent was found not guilty of assault. The Heritage Foundation is in “open revolt” after its president defended Tucker Carlson for hosting white supremacist Nick Fuentes. Staffers, including members of its antisemitism task force, have quit. Meanwhile, FIFA announced a mysterious new “peace prize” ahead of the World Cup draw in D.C., which insiders say Trump demanded after missing out on a Nobel. And Tesla's board is set to hand Elon Musk a $1 trillion compensation deal. Resources/Articles mentioned in this episode: Politico: House Oversight Democrats call on embattled royal Andrew Windsor to testify - Live Updates Politico: California's attorney general endorses Scott Wiener to succeed Pelosi NYT: Judge Orders Trump Administration to Fully Fund SNAP Benefits This Month WaPo: Trump, long fixated on ‘fat drug,' announces deal to lower its price WaPo: Jury finds D.C. ‘sandwich guy' not guilty of assaulting officer WaPo: Heritage staff in open revolt over leader's defense of Tucker Carlson Axios: Trump teased as possible first FIFA Peace Prize winner CNBC: Elon Musk expected to prevail in Tesla shareholder vote over CEO's $1 trillion pay plan  Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

¡Emprendeduros! En este episodio Rodrigo nos da una actualización de mercado donde habla del estatus del mercado, del mercado de empleo y de la manufactura en el pais. Nos da los reportes de ingresos de Palantir, Uber, Shopify, AMD, Novo Nordisk, McDonald's y AppLovin. Después habla de la compra de Kenvue por Kimberly Clark y de la semana ocupada de Elon Musk. Finalmente contestara unas preguntas de los Emprendeduros. ¡Síguenos en Instagram! Rodrigo: https://www.instagram.com/rodnavarro Emprendeduros: https://www.instagram.com/losemprendeduros Para mas información sobre nuestro fondo visita: https://emprendedurosventures.com/

The White House has struck a deal with two more drugmakers: Eli Lilly and Novo Nordisk. Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz discusses the administration's plan to make GLP-1s more affordable for Americans. Tesla shareholders voted to approve Elon Musk's $1 trillion pay package, as long as he reaches their lofty goals for the company. Musk biographer Walter Isaacson discusses the plan of milestones and Musk's history of exceeding investor expectations. Plus, U.S. airlines are beginning to cancel flights to manage shutdown-strained staffing of air traffic controllers, and Warren Buffett issued a warning on AI.  Dr. Mehmet Oz - 21:43Walter Isaacson - 38:56 In this episode:Dr. Mehmet Oz, @DrOzJoe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkinKatie Kramer, @Kramer_Katie Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

//The Wire//2300Z November 6, 2025////ROUTINE////BLUF: RIOTS ERUPT IN BIRMINGHAM AS SPORTS MATCH TRANSITIONS FROM GENERAL HOOLIGANISM INTO LARGER GEOPOLITICAL CONFLICT. OVAL OFFICE PRESS CONFERENCE HALTED DUE TO PHARMA EXEC COLLAPSING SUDDENLY.// -----BEGIN TEARLINE------International Events-United Kingdom: A state of civil unrest has emerged following a soccer match inflaming local tensions. Following a much-anticipated soccer match between a team from Tel Aviv and the local Aston Villa team in Birmingham, riots broke out overnight as rival gangs took their disputes to the street. Riot police were deployed to the stop the roving bands of "youths" from destroying property and generally causing disarray. Throughout the day today, the unrest has continued as long-held social tensions in Birmingham reached the boiling point. Over 700x police officers have been called up for duty tonight as the riots are planned to become much more significant with tonight's match against Tel Aviv.-HomeFront-Washington D.C. - This afternoon the White House announced a special press conference on the topic of pharmaceuticals. Most notably the press conference was called to announce a partnership with Novo Nordisk to lower the price of the Ozempic drug when purchased through the TrumpRX program.Analyst Comment: The press conference was abruptly cut short after Gordon Findlay, one of the senior executives of Novo Nordisk (the maker of Ozempic) collapsed in the Oval Office during the live broadcast. Dr. Oz, who was a part of the conference tried to render aid to him, and the rest of the press conference was delayed while Findlay received medical treatment. It's not certain why he dropped, but the White House stated that he was okay but feeling a bit lightheaded after the incident.-----END TEARLINE-----Analyst Comments: Once more, the misfortune of our friends across the pond gives Americans absolutely critical insight as to how things might go if a similar series of events were to pop off here in a major American city. For obvious reasons, a relatively nondescript soccer match is less about the sport and more about social and political issues, thus the unrest concerns. In short, it's a fairly kinetic and complex situation that serves in many ways as an indicator of the future to come.Birmingham has become a huge focal point for migrant housing, and these riots were not the work of the indigenous English. However, as with all soccer hooliganism, the rioting is almost never just one-sided. In this case, some (not all) Maccabi Tel Aviv fans were banned by British authorities from the Aston Villa stadium after starting a riot themselves, according to police. This resulted in two things happening simultaneously: the Islamic population of Birmingham rejoiced at this perceived geopolitical victory (and celebrated by breaking things and causing a ruckus), while many other Maccabi Tel Aviv fans lashed out in anger (again, also by breaking things and causing a ruckus). However, during the general state of unrest, rival gangs of mostly black and Islamic migrants (which had no interest in soccer) started fighting amongst themselves, adding in more diversity to the evening fray. Others still showed up to protest for more political purposes, but remained relatively calm throughout the evening. When the police arrived to restore order as this was getting underway last night (the day before the match), the more active elements of the crowds turned on them, targeting them with fireworks (which were probably used due to yesterday being Guy Fawkes Night). It is this unrest that continued from last night, throughout the day today, to tonight as well (the night of the match). So this is a two-day affair, not just a one-and-done scuffle, but a more prolonged period of unrest.In short, what's going on in Birmingham right now is more or less a state of mild pandem

Eric Criscuolo, Market Strategist at the NYSE, recaps a week where markets pulled back as Tech lost steam and defensive sectors gained ground. The Fed cut rates as expected, but Chair Powell's hawkish tone cooled hopes for further easing. Political headlines added uncertainty, with Democrats outperforming on Election Day and the Supreme Court questioning Trump-era tariffs. M&A activity surged, led by Kimberly Clark's $50B bid for Kenvue and a pharma bidding war between Pfizer and Novo Nordisk. Investors now look ahead to key earnings, economic data, and the impact of the government shutdown as the year-end trading calendar tightens.

Mehr Infos zum Kreditangebot von unserem Partner Scalable Capital findet ihr hier: https://de.scalable.capital/credit. Zalando und DHL liefern, Börse jubelt. Datadog überzeugt. Eli Lilly und Novo Nordisk haben Deal mit Trump. Duolingo will wachsen und nicht profitabel werden, Börse schimpft. Marvell wurde fast gekauft, HelloFresh hat Short-Attacke und Take-Two verschiebt GTA VI wieder. Lemonade (WKN: A2P7Z1) will das OpenAI der Versicherungswelt werden. Klappt das? Quantencomputing-Aktien waren an der Börse in den letzten Monaten Highflyer. Wie funktioniert die Technologie, wie funktioniert der Markt und wie erkennt man vertrauensvolle Firmen? Daniel Volz von Kipu Quantum klärt auf. Diesen Podcast vom 07.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Millions of Americans will soon have direct access to popular weight-loss drugs at far lower prices than they pay now. That’s due to a deal announced between President Trump and pharmaceutical giants Eli Lilly and Novo Nordisk. William Brangham discussed the deal and its potential impact with Stacie Dusetzina of Vanderbilt University. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Gear up, freedom fighters—@intheMatrixxx and @shadygrooove charge into Season 7, Episode 212, "Trump Makes Announcement; Erika Kirk 1st Interview," dismantling deep-state distractions while spotlighting President Trump's powerhouse move to slash obesity drug prices to $149 a month for many Americans through deals with Eli Lilly and Novo Nordisk. As relentless exposers of globalist schemes, the hosts dissect this win for everyday patriots against Big Pharma greed, then pivot to Erika Kirk's raw, faith-fueled first TV sit-down since her husband Charlie Kirk's tragic assassination, where she honors his Turning Point USA legacy and stands firm amid loss. With sharp live breakdowns and unyielding America-First analysis, they equip you to reject establishment spin and defend sovereignty. The truth is learned, never told—the constitution is your weapon. Tune in at noon-0-five Eastern LIVE to stand with Trump! Trump, drug prices, Erika Kirk, Charlie Kirk, America First, MG Show, @intheMatrixxx, @shadygrooove, Turning Point USA, Big Pharma, patriotic intel mgshow_s7e212_trump_makes_announcement_erika_kirk_1st_interview Tune in weekdays at 12pm ET / 9am PST, hosted by @InTheMatrixxx and @Shadygrooove. Catch up on-demand on https://rumble.com/mgshow or via your favorite podcast platform. Where to Watch & Listen Live on https://rumble.com/mgshow https://mgshow.link/redstate X: https://x.com/inthematrixxx Backup: https://kick.com/mgshow PODCASTS: Available on PodBean, Apple, Pandora, and Amazon Music. Search for "MG Show" to listen. Engage with Us Join the conversation on https://t.me/mgshowchannel and participate in live voice chats at https://t.me/MGShow. Social Follow us on X: @intheMatrixxx https://x.com/inthematrixxx @ShadyGrooove https://x.com/shadygrooove Follow us on YouTube: ShadyGrooove https://www.youtube.com/c/TruthForFreedom Support the show: Fundraiser: https://givesendgo.com/helpmgshow Donate: https://mg.show/support Merch: https://merch.mg.show MyPillow Special: Use code MGSHOW at https://mypillow.com/mgshow for savings! Wanna send crypto? Bitcoin: bc1qtl2mftxzv8cxnzenmpav6t72a95yudtkq9dsuf Ethereum: 0xA11f0d2A68193cC57FAF9787F6Db1d3c98cf0b4D ADA: addr1q9z3urhje7jp2g85m3d4avfegrxapdhp726qpcf7czekeuayrlwx4lrzcfxzvupnlqqjjfl0rw08z0fmgzdk7z4zzgnqujqzsf XLM: GAWJ55N3QFYPFA2IC6HBEQ3OTGJGDG6OMY6RHP4ZIDFJLQPEUS5RAMO7 LTC: ltc1qapwe55ljayyav8hgg2f9dx2y0dxy73u0tya0pu All Links Find everything on https://linktr.ee/mgshow Intermission Music Lemurian Shores (with Lucentia) (~432 Hz) by Spheriá | https://soundcloud.com/spheriamusic Music promoted by https://www.chosic.com/free-music/all/ Creative Commons CC BY-SA 3.0 https://creativecommons.org/licenses/by-sa/3.0/

A federal judge ruled Thursday that the Trump administration must fully fund SNAP benefits amid the government shutdown, giving officials until Friday to secure the money. Meanwhile, as the shutdown continues, 40 major U.S. airports—including Los Angeles International, John F. Kennedy International, and Chicago O'Hare—will face a 10 percent reduction in flights starting Friday.President Donald Trump, just one day after Supreme Court arguments on his sweeping global tariffs in a case he called “one of the most important cases in the history of our country,” is doubling down—emphasizing that his tariff threats against Beijing were a national security lifeline that forced Xi Jinping to the negotiating table. The president is also set to meet with the leaders of all five Central Asian countries Thursday night as the United States works to expand its influence in a region increasingly courted by China.Trump also announced new agreements to expand access to and reduce the cost of weight loss drugs. The deals with pharmaceutical companies Novo Nordisk and Eli Lilly will broaden coverage for Medicare and Medicaid recipients and lower the prices paid by the federal government.

Millions of Americans will soon have direct access to popular weight-loss drugs at far lower prices than they pay now. That’s due to a deal announced between President Trump and pharmaceutical giants Eli Lilly and Novo Nordisk. William Brangham discussed the deal and its potential impact with Stacie Dusetzina of Vanderbilt University. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

President Trump strikes a groundbreaking deal with Eli Lilly and Novo Nordisk to slash prices on popular weight-loss drugs for Medicare, Medicaid, and out-of-pocket patients. Nov 6th 2025 --- Please Like, Comment and Follow 'The Ray Appleton Show' on all platforms: --- 'The Ray Appleton Show’ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- 'The Ray Appleton Show’ Weekdays 11 AM -2 PM Pacific on News/Talk 580 AM & 105.9 KMJ | Website | Facebook | Podcast | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

President Donald Trump announced a major initiative aimed at lowering the cost of popular weight loss drugs in the U.S. Pres. Trump unveiled deals with Eli Lilly and Novo Nordisk to reduce prices on Wegovy (Novo Nordisk), Zepbound (Eli Lilly) and potential inclusion of Ozempic, primarily a diabetes drug also used for weight loss. Please Like, Comment and Follow 'Broeske & Musson' on all platforms: --- The ‘Broeske & Musson Podcast’ is available on the KMJNOW app, Apple Podcasts, Spotify or wherever else you listen to podcasts. --- ‘Broeske & Musson' Weekdays 9-11 AM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Facebook | Podcast| X | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

Unser Partner Scalable Capital ist der einzige Broker, den deine Familie zum Traden braucht. Bei Scalable Capital gibt's nämlich auch Kinderdepots. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Novo Nordisk enttäuscht schon wieder, Siemens Healthineers auch. McDonald's, BMW und Vestas überraschen dafür positiv. Apple zahlt die nächste Mrd. an Google. Milliardär Carl Icahn kauft sich in US-Werkstattkette Monro ein und Snap kooperiert mit Perplexity. Alle Probleme können KI, Cloud und Co. nicht lösen. Den Abfluss von Wasser zum Beispiel. Dafür braucht es Rohre und Drainagen, und die hat Advanced Drainage Systems (WKN: A117FL). MetaMask ist einer der bekanntesten Krypto-Wallet-Anbieter. Jetzt plant die Muttergesellschaft Consensys offenbar einen Börsengang zu einer Milliardenbewertung. Außerdem geht's um den Krypto-Crash der letzten Tage. Diesen Podcast vom 06.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Dommer afviser Pfizers forsøg på at stoppe Novo-bud. Novo Nordisk må igen skrue ned for forventningerne. Vestas har succes med landvind og aktierne brager op med 15 pct. Ørsted lander milliardunderskud igen. Pandora skuffer og aktien falder. USA's nedlukning rammer nu også lufthavne. Højesteret vurderer Trumps toldkrig. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

AI and speculative stocks slide again. The FAA is cutting flights by 10% at 40 major airports due to the government shutdown.  And President Trump announces deals with Eli Lilly and Novo Nordisk to cut the cost of weight loss drugs.    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hvilken betydning får ny karakterskala? Hvordan kan lukningen af valgsteder påvirke et kommunalvalg? Og laver Novo Nordisk ulovlig reklame? Dagens værter: Julie Toft og Bjarne Steensbeck.

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen?

Learn more about your ad choices. Visit megaphone.fm/adchoices

A.M. Edition for Nov. 5. Democrats notched major victories last night, prompting President Trump's ire on social media. WSJ editor Aaron Zitner breaks down what the results mean for both parties and how they could shape the national political landscape going into the 2026 midterms. Plus, Republican senators meet at the White House this morning as the government shutdown becomes the longest in history. And we look at the competition facing weight-loss giant Novo Nordisk. Caitlin McCabe hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus, Republican senators meet at the White House this morning as the government shutdown becomes the longest in history. And we look at the competition facing weight-loss giant Novo Nordisk. Caitlin McCabe hosts.  Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sara Eisen, Carl Quintanilla, and David Faber kicked off the hour with a slew of fresh data on the economic front - and more on what investors need to know as the Supreme Court kicks off Day 1 of arguments around the legality of President Trump's global tariffs... Plus: Bank of America CEO Brian Moynihan joined the team with his read on the economy, live from the company's first investor day in more than 15 years - while the CEO of Lemonade gave his take on how AI is changing the insurance business as those shares surge post-results.  Also in focus: the growing bidding war between Novo Nordisk and Pfizer that could impact the future of the weightloss market... and a deep-dive on what's driving Pinterest shares to their worst day on record. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On today's episode of The Gist Healthcare Podcast, CMS finalizes a Medicare pay bump for physicians. Kimberly-Clark to purchase Tylenol maker Kenvue, and Pfizer sues to block Novo Nordisk's merger with an obesity startup. Hosted on Acast. See acast.com/privacy for more information.

Listen to Daily Global #News from Grecian Echoes WNTN 1550 AM -  Democrats won the races in the first major elections since Trump became president - Trump is negotiating a deal with Eli Lilly and Novo Nordisk that would lower obesity drug price - The government shutdown has entered its 36th day, setting a new record

Did you know your sleep habits could be affecting your weight? Join us with Dr. Michael Mak as he explains the powerful connection between sleep and obesity, why sleep is essential for overall health, and tips for getting a better night's rest.The medical information in this podcast is provided as an information resource only. It is not in any way intended to be nor should you rely on it as a substitute for professional medical evaluation, diagnosis, advice and treatment.This episode was sponsored by Novo Nordisk. It was created independently by My Weight - What to Know with no influence from Novo Nordisk.

Novo Nordisk has cut its forecast for the fourth time this year, after disappointing sales of its blockbuster drugs Wegovy and Ozempic. It underscores the challenges facing its new chief executive Mike Doustdar. He spoke to Bloomberg's Guy Johnson about the experience so far. See omnystudio.com/listener for privacy information.

From Wall Street to Main Street, the latest on the markets and what it means for your money. Updated regularly on weekdays, featuring CNBC expert analysis and sound from top business newsmakers. Anchored by CNBC's Jessica Ettinger. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Stock market update for November 5, 2025.Follow us on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@therundowndaily⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠This video is for informational purposes only and reflects the views of the host and guest, not Public Holdings or its subsidiaries. Mentions of assets are not recommendations. Investing involves risk, including loss. Past performance does not guarantee future results. For full disclosures, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Public.com/disclosures⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

Det er en af årets helt store regnskabsdage, og Millionærklubben står klar til at vurdere de økonomiske ståsteder og fremtidsudsigter for bl.a. Novo Nordisk, Vestas og Pandora. Aktiechef i HC Andersen Capital, Michael Friis Jørgensen, og CEO i Global Health Invest, debatterer desuden den lettere bekymrede stemning, der synes at krybe ind over flere af de globale aktieindeks, og sidst i udsendelsen blander senior aktieanalytiker Søren Løntoft Hansen sig i debatten om Novos regnskab på en telefon fra Sydbank i Aabenraa. Vært: Bodil Johanne Gantzel See omnystudio.com/listener for privacy information.

Global markets are in the red as concerns mount over A.I. stocks being over-valued, prompting a tech sell-off. In the U.S., Democrats record wins in key gubernatorial races in Virginia and New Jersey while in New York City, far-left candidate Zohran Mamdani claims victory to become mayor. Danish pharma giant Novo Nordisk slashes its top-end forecasts as sales growth expectations for its flagship obesity drugs tumble.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

APAC stocks were mixed after an early sell-off following the losses stateside, where tech underperformed amid valuation concerns.European equity futures indicate a lower cash market open with the Euro Stoxx 50 future down 0.7% after the cash market closed with losses of 0.3% on Tuesday.The USD rally has paused for breath (DXY remains above 100), EUR/USD is unable to reclaim 1.15 status, USD/JPY failed to hold below 153.Global fixed income benchmarks remain supported, crude futures lack direction, Gold remains below USD 4k.Looking ahead, highlights include German Industrial Orders, EZ, UK & US Final PMI, EZ Producer Prices, US ADP, US ISM Services PMI, Riksbank, NBP & BCB Policy Announcements, ECB Wage Tracker, US Supreme Court Tariff hearing begins, Speakers including ECB's Nagel, BoE's Breeden, BoC's Macklem & Rogers, Riksbank's Jansson, US QRA, Supply from Germany.Earnings from BMW, Novo Nordisk, Pandora, AMC, Arm, Snap & McDonald'sRead the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Ahold Delhaize overtreft de verwachting van analisten. De winst én omzet vallen in het derde kwartaal hoger uit. Het bedrijf gaat daarom (opnieuw) eigen aandelen inkopen. Voor 1 miljard euro. Ook investeert het supermarktbedrijf in AI. Deze aflevering hebben we het over die stap. Gaat het Ahold verder helpen? De marges verbeteren nu al, maar kunnen misschien nóg meer groeien. Hebben we het ook over de Amerikaanse shutdown. Dat is nu officieel de langste uit de Amerikaanse geschiedenis. Al 36 dagen zit de boel daar op slot en een einde is nog lang niet in zicht. Wij proberen te kijken wat dat betekent voor de Amerikaanse economie, voor de beurs en voor jou als belegger.Een shutdown die de beursgang van The Magnum Ice Cream Company in de war schopte. Die werd vertraagd, maar er kwam vandaag toch goed nieuws. Op 8 december gaat de ijsjestak alsnog naar de beurs van New York, Londen én Amsterdam! Kwartaalcijfers zijn er ook van Toyota, Novo Nordisk en Wolters Kluwer. We vertellen je waar je op moet letten. Waarom de cijfers van McDonalds zo goed zijn én over een Nederlands beursbedrijf dat mogelijk het Damrak gaat verlaten.See omnystudio.com/listener for privacy information.

Regeringen er klar med et nyt boligforslag. Mange store regnskaber lander i dag og i morgen. Novo Nordisk er klar til at byde endnu mere for medicinproducent. En drænet russisk økonomi. EU i klemme. Staten vil købe land for milliarder. Vært: Trine Duvander (trine.duvander@borsen.dk)

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit einem der besten YouTube-Kanäle zu Aktien & Investments. https://www.youtube.com/@scalable.capital/videos Novo Nordisk und Pfizer streiten, Metsera freut's. Norwegen will keine 1.000 Mrd. für Musk, Fresenius will weniger FMC, AMD und Uber haben Zahlen. Big-Short-Investor wettet gegen NVIDIA & Palantir, Telefonica halbiert Dividende und Nintendo verkauft mehr Switch 2. Spotify (WKN: A2JEGN) erhöht die Preise und hat mehr Premium-Kunden. Bald hat Spotify auch mehr Video-Podcasts bei Netflix. Schlecht für YouTube, gut für Spotify? Goldminenaktien sind wohl eine der komplexesten Assetklassen. Wie soll man bei der Analyse vorgehen und welche Kennzahlen sind wichtig? Wir klären's. Diesen Podcast vom 05.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

En Capital Intereconomía hemos seguido en directo la apertura del Ibex 35 y del resto de bolsas europeas, que arrancan la sesión a la baja siguiendo la estela de Wall Street, arrastradas por el miedo a una posible burbuja en la inteligencia artificial y la huida de los inversores hacia activos refugio. En el análisis de mercados, Patricia García, socia fundadora de MacroYield y directora del Máster en Finanzas de ESIC Business & Marketing School, ha explicado las causas del pánico bursátil que domina los mercados. La experta destacó la fuerte demanda de bonos del Tesoro estadounidense, cuya rentabilidad a 10 años ha caído a mínimos de la última semana, reflejando la búsqueda de seguridad por parte de los inversores. Se han volatilizado 500.000 millones de dólares de capitalización en el mercado tecnológico, lo que reaviva las dudas sobre una posible corrección estructural tras meses de subidas impulsadas por la euforia de la IA. En el plano corporativo, Novo Nordisk redujo previsiones de crecimiento para sus fármacos de pérdida de peso ante la presión sobre los precios, mientras que Ørsted mantuvo sus estimaciones para el año. Además, el cierre de Gobierno en Estados Unidos se convierte ya en el más largo de la historia, añadiendo más incertidumbre al panorama económico global. La jornada se completó con el consultorio de bolsa, dirigido por Miguel Méndez, analista independiente, quien analizó valores clave y las oportunidades que pueden surgir en un contexto de corrección.

En Capital Intereconomía hemos puesto hoy el foco empresarial en Ørsted, dentro de una jornada en la que los mercados siguen marcados por la volatilidad y la búsqueda de refugio en la renta fija. En el Radar Empresarial, analizamos junto a Xavier Brun, responsable de Renta Variable Europea en Trea AM, la situación de Novo Nordisk, que ha anunciado una rebaja en sus previsiones de crecimiento para sus principales tratamientos contra la obesidad y la diabetes. Brun explicó que, aunque la compañía sigue registrando beneficios sólidos —un 4% más interanual—, el mercado reacciona con cautela ante el aumento de la competencia y la presión sobre los precios de los medicamentos para la pérdida de peso. El analista señaló que la entrada de nuevos rivales, como Metsera, podría redefinir las valoraciones del sector y forzar a Novo Nordisk a ajustar su estrategia de precios y márgenes. Aun así, considera que la farmacéutica danesa sigue manteniendo una posición de liderazgo, con un modelo de negocio sólido y márgenes resistentes a medio plazo. En el Foro de la Inversión, Martina Álvarez, directora de Ventas para Iberia de Janus Henderson, abordó el papel de la renta fija como refugio en el contexto actual de incertidumbre y destacó que las próximas decisiones de los bancos centrales serán clave para definir el rumbo de los mercados en el cierre del año. La jornada concluyó con el consultorio de fondos, en el que Diego González, socio director de Cobalto Inversiones EAFI, respondió a los oyentes sobre estrategias de inversión, fondos defensivos y oportunidades en renta fija y variable global.

Avalancha de resultados en Europa con el foco en Siemens Healthineers, Vestas, Fresenius, Novo Nordisk y la francesa Bouygues. Con Alberto Roldán, profesor de finanzas de la Universidad Europea.

The ASX200 fell about 0.25% to a two month low after the RBA kept rates steady and signalled only one cut in 2026. Material and tech stocks led losses, while financials rose on Westpac earnings. US government shutdown and a 2% tech slide added pressure. Look out for US earnings from McDonald’s, Snap and Novo-Nordisk, plus NAB and Macquarie results this week. The content in this podcast is prepared, approved and distributed in Australia by Commonwealth Securities Limited ABN 60 067 254 399 AFSL 238814. The information does not take into account your objectives, financial situation or needs. Consider the appropriateness of the information before acting and if necessary, seek appropriate professional advice.See omnystudio.com/listener for privacy information.

Many of the top stories of 2025 are currently being written. We're on the edge of our keyboards, watching and waiting as Pfizer and Novo Nordisk duke it out over the right to acquire glittery obesity startup Metsera. In the latest development, Pfizer raised its original bid of around $7.27 billion to about $8.1 billion on Monday—only to be usurped again by the indefatigable Novo, which upped its own bid to a cool $10 billion.  Meanwhile, the unprecedented drama in the uppermost ranks of the FDA—another top story of 2025—continues as CDER Director George Tidmarsh exits the agency. Tidmarsh reportedly resigned Sunday after being placed on administrative leave amid an investigation into his “personal conduct” at the agency. On Monday, however, Tidmarsh told Endpoints News that he was “second-guessing” his decision.  Speaking of the FDA, the regulator appears to have done its own 180—on uniQure's investigational gene therapy for Huntington's disease, three-year data from which sent the biotech's stock into the stratosphere just five weeks ago. Despite previous agreements on protocols and statistical analyses, the agency “no longer agrees” that Phase I/II data for AMT-130 are adequate to provide primary evidence for the application, uniQure said, throwing the timeline for the BLA into question.  Another gene therapy player, Sarepta Therapeutics, took a hit this week, as two of its Duchenne muscular dystrophy drugs, Vyondys 53 and Amondys 45, failed a confirmatory trial. Sarepta still plans to file for full approval of the two exon-skipping therapies, however, based on what it called “encouraging trends” in efficacy. Finally, on the genetic medicine front, CBER director Vinay Prasad teased an upcoming paper that will detail the regulator's thinking and a new approach to gene editing approvals.  On top of all that, Q3 earnings continue to roll in, with Pfizer, Eli Lilly, Vertex, Bristol Myers Squibb, AbbVie, and more reporting results.  One more thing: Have you ever wanted to know more about the inner workings of the Biogen-Eisai Alzheimer's partnership? Check out this profile on BioSpace 40 under 40 honoree Neena Bitritto-Garg, Eisai alum and current CEO of Ensho Therapeutics. 

Massiv udrensning i medarbejderstaben, ny topchef, og snart helt ny bestyrelse. Tingene går stærkt i Novo i disse måneder, men spørger man Finans´ erhvervskommentator Søren Linding, er der også god grund til det, når man ser på selskabets regnskab for 3. kvartal: "Der er krise over næsten hele linjen. Hvis du sidder og kigger på tallene fra dagens regnskab så taber Novo Nordisk kæmpe store markedsandele." Hør i denne Lyn-analyse, hvorfor det går så galt, hvem Novo taber til. og hvad selskabet gør mere præcist for at rette skuden op. Gæst: Søren Linding, erhvervskommentator og debatredaktør, Finans. Vært: Mads Ring. Foto: Mads Claus Rasmussen.See omnystudio.com/listener for privacy information.

Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb and Merck, say about the future of the industry and how companies are responding to President Trump's drug-pricing plans, including TrumpRx. WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Further Reading: Novo Nordisk Sweetens Offer for Metsera - WSJ Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk The Day Pharma's Weight-Loss Gold Rush Intensified Pfizer Profit Falls Amid Lower Covid-19 Drug Demand Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera Novo Nordisk to Shake Up Board After Obesity-Market Challenges Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings AbbVie Lifts Profit Outlook as Sales Rise Bristol Myers Squibb Profit Soars, Raises Revenue Guidance Merck Profit Rises on Strong Keytruda Demand GSK Lifts Guidance After Specialty Medicines Boost Sales Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains Learn more about your ad choices. Visit megaphone.fm/adchoices

Palantir lifted its 2025 revenue guidance and Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug start-up Metsera. Plus, OpenAI inked a $38bn computing deal with Amazon, and the FT's Claire Jones explains how the Trump administration is considering pushing for wider global dollar adoption. Mentioned in this podcast:Palantir lifts 2025 sales outlook after posting strong quarterly growthPfizer files second lawsuit to block Novo Nordisk's $9bn Metsera bidOpenAI strikes $38bn computing deal with AmazonUS pushes for wider global dollar adoptionToday's FT News Briefing was produced by Sonja Hutson, and Marc Filippino. Our show was mixed by Kelly Garry. Additional help from Michela Tindera, Michael Lello and David da Silva. The FT's acting co-head of audio is Topher Forhecz. The show's theme music is by Metaphor Music.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Plus: First Brands' new management accuses founder Patrick James of fraud. And Stellantis's Chrysler recalls over 300,000 hybrid Jeeps over battery fire risks. Zoe Kuhlkin hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

The tech sector under pressure: Carl Quintanilla, Jim Cramer and David Faber began the show with Palantir shares down sharply despite better-than-expected Q3 results and upbeat revenue guidance. Hear what CEO Alex Karp told CNBC about short sellers as Palantir shares remain among this year's best performers on the S&P 500. Pfizer and Novo Nordisk sweetened their respective offers to buy obesity drugmaker Metsera. Norway's sovereign wealth fund — the world's biggest — said it will vote against Tesla CEO Elon Musk's massive pay package that could total $1 trillion. Shopify President Harley Finkelstein joined the program to discuss the company's earnings and its outlook for the holiday quarter. Also in focus: Earnings winners and losers. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Novo Nordisk's unsolicited $8.5 billion bid for Metsera has thrown a wrench into Pfizer's plans to return to the obesity race via its acquisition of the New York-based start-up. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the details of the competing bids and what's at stake for the pair of suitors.The analysts also assess the reasons behind the abrupt departure of Center for Drug Evaluation and Research Director George Tidmarsh from FDA and a surge in activity on the Hong Kong stock exchange. This episode of the BioCentury This Week podcast is brought to you by Voyager Therapeutics.View full story: https://www.biocentury.com/article/657475#Biotech #PharmaDeals #ObesityDrugs #MergersAndAcquisitions #FDA #LifeSciences #GlobalBiotech #HongKongMarket00:01 - Sponsor Message: Voyager Therapeutics01:53 - Metsera M&A15:23 - Tidmarsh Ouster25:12 - Hong Kong IPOsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Ørsted sælger halvdelen af stor havvind­møl­le­park. Pfizer anlægger endnu en sag mod Novo Nordisk. Ny medicinalfabrik i Europa. Prisstig­ninger svækker forsik­rings­kun­ders tillid. Ukrainsk våbenkontor i København. Vært: Trine Duvander (trine.duvander@borsen.dk)

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of healthcare, from strategic mergers and regulatory shifts to groundbreaking advancements in drug development.Let's begin with a monumental merger that signals a shift towards more integrated healthcare solutions. The $48.7 billion acquisition of Kenvue, a consumer health spinout from Johnson & Johnson, by Kimberly-Clark illustrates the growing convergence between consumer health products and traditional pharmaceuticals. This strategic move highlights a trend towards expanding product portfolios and enhancing distribution networks, aiming to better address comprehensive patient needs. Mergers like these could redefine how healthcare products are marketed and delivered, emphasizing holistic approaches to patient care.Turning to regulatory news, the resignation of Dr. George Tidmarsh from the FDA due to controversial communications has spotlighted the ongoing challenges within regulatory oversight. This incident underscores the delicate balance regulators must maintain in ensuring transparency while safeguarding sensitive information. Such developments are crucial as they directly affect public trust in drug approval processes and the industry's ability to navigate complex regulatory landscapes.In scientific advancements, Roche is making significant progress with its drug Gazyva for autoimmune diseases. Following FDA approval for lupus-related kidney disease, promising Phase 3 trial results for systemic lupus erythematosus (SLE) are propelling Roche closer to offering new hope for patients with this chronic condition, which currently has limited effective treatments. This success underscores the potential of targeted therapies in transforming treatment paradigms for autoimmune diseases.Eli Lilly's $3 billion investment in a new manufacturing facility in the Netherlands marks a strategic effort to bolster oral medicine production globally. This expansion not only reinforces Lilly's commitment to meeting global demand but also reflects an industry-wide trend towards investing in scalable manufacturing capabilities. Such moves are critical for ensuring supply chain resilience and addressing rising healthcare needs worldwide.In legal news, Pfizer's fierce competition with Metsera over Novo Nordisk's counteroffer highlights the high stakes involved in securing promising assets within the biotech sector—a sector particularly focused on obesity treatment due to its substantial market growth potential. The outcome of this legal battle could influence future strategic partnerships and acquisitions, demonstrating the intense competition among pharmaceutical giants.Meanwhile, UniQure faces challenges as its gene therapy for Huntington's disease encounters regulatory hurdles with the FDA. Despite initial expectations as a groundbreaking treatment, this setback emphasizes the rigorous scrutiny gene therapies undergo to ensure safety and efficacy. Such hurdles highlight the complexities of advancing novel therapies through regulatory pathways.Policy developments are also reshaping drug pricing structures as evidenced by HRSA's approval of eight drugmakers' plans for a 340B rebate model pilot program. This initiative aims at optimizing pricing structures while balancing cost containment with access to essential medications for underserved populations—a critical concern in today's healthcare landscape.International collaborations continue to play a pivotal role in accelerating drug discovery and development. Neurocrine Biosciences' $880 million deal with China's TransThera Sciences exemplifies such partnerships, focusing on emerging therapeutic areas like immunology. These collaborations are vital in leveraging global expertise and resources to drive innovatSupport the show

Danmark har Novo Nordisk, Sverige har AstraZeneca – hva har Norge? Vi ser på hvorfor norsk bioteknologi fortsatt er et uutnyttet potensial, og hvordan Radiumhospitalet likevel skaper selskaper i verdensklasse. Med Øystein Soug (Oncoinvent) og Erling Nordbø (Aleap Ventures) snakker vi om hvordan vi kunne ligget langt foran med politisk vilje og et veikart som faktisk følges.

Plus: Pfizer files a second lawsuit against Metsera and Novo Nordisk. And OpenAI pays Amazon $38 billion for computing power in a multiyear deal. Zoe Kuhlkin hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Get the latest buzz on GLP-1 therapies and the future of metabolic medicine! This episode provides an in-depth look at what's coming out of Obesity Week in Atlanta, GA, featuring expert insights from Dave Knapp from On the Pen.Key Topics & Breakthroughs:Corporate Battle for Biotech: We break down the surprise counteroffer by Novo Nordisk to acquire Metsera, the obesity biotech company that Pfizer had recently announced it was buying, setting the stage for a major pharmaceutical turf war.Pipeline Watch: Dive into the plethora of new therapies in current clinical trials, including the latest developments from Viking Therapeutics and the push for Oral GLP-1s.GLP-1's New Frontier: Discover the groundbreaking research on GLP-1's potential role in treating alcohol and narcotics addictions. We also discuss Brenipatide and its surprising dual focus on alcohol abuse and asthma.Tune in for a comprehensive review of the medications, mergers, and clinical trials shaping the next generation of weight loss and metabolic treatments.______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy #ObesityCare #PatientAdvocate #GLP1Community #RealGLP1StoriesSend us Fan Mail! GetClaimable.com/PlusSideZ to appeal your GLP-1 Insurance Denails and use code PlusSideZ to save! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==